Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of nilotinib by cobinding of asciminib. Oruganti B, Lindahl E, Yang J, Amiri W, et al. J Biol Chem 2022;298:102238.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Oruganti B, Lindahl E, Yang J, Amiri W, et al. Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of nilotinib by cobinding of asciminib. J Biol Chem 2022;298:102238.
PMID: 35809644